/주식/IXHL
IXHL

IXHL

USD

Incannex Healthcare Inc. Common Stock

$0.339-0.005 (-1.480%)

실시간 가격

Healthcare
Drug Manufacturers - Specialty & Generic
호주

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$0.344

고가

$0.349

저가

$0.336

거래량

15.84M

기업 기본 정보

시가총액

118.0M

산업

Drug Manufacturers - Specialty & Generic

국가

Australia

거래 통계

평균 거래량

66.44M

거래소

NCM

통화

USD

52주 범위

저가 $0.08현재가 $0.339고가 $3.12

관련 뉴스

GlobeNewswire

Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder

MELBOURNE, Australia and NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company") is pleased to report positive data from its Phase 2 clinical trial of PSX-001

더 보기
Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder
GlobeNewswire

Incannex Healthcare Authorizes $20 Million Share Repurchase Program

MELBOURNE, Australia and NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative combination

더 보기
Incannex Healthcare Authorizes $20 Million Share Repurchase Program
GlobeNewswire

Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea

MELBOURNE, Australia and NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage pharmaceutical company developing innovative combination therapies for prevalent medical

더 보기
Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea